4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” This case-control study from Lombardy, Italy, observed that men over 55 taking 5-alpha reductase inhibitors for benign prostatic hyperplasia were hospitalized for COVID-19 at a lower rate than age-matched controls, suggesting potential protective effects against severe disease.
6 citations
,
January 2024 in “Cancers” This systematic review found that antiandrogens do not appear to protect against SARS-CoV-2 infection or reduce COVID-19 severity, suggesting their use is not advisable for COVID-19 treatment.
7 citations
,
December 2019 in “American Journal of Clinical Dermatology” This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.
5 citations
,
December 2022 in “Viruses” This review highlights recent insights into using antiandrogens as preventive and therapeutic measures against COVID-19, emphasizing their role in blocking viral infection by modulating androgen-mediated host protease TMPRSS2 and cell entry protein ACE2, with varying success in clinical trials.
This review summarizes the latest updates on using antiandrogens as potential prophylactic and therapeutic options for COVID-19, highlighting that androgen-mediated regulation of factors like TMPRSS2 and ACE2 is involved in SARS-CoV-2 infection, suggesting a strategy to block viral entry into cells.